Lilly says solanezumab data suggest disease-modifying effect

Eli Lilly and Co. (NYSE:LLY) reported results from two Phase III studies and an extension study of solanezumab showing that patients with mild Alzheimer's disease (AD) who started treatment immediately retained a benefit in cognitive and functional treatment effects compared to patients who delayed treatment by 80 weeks.

In an abstract from a presentation at the Alzheimer's Association International Conference in Washington, D.C., researchers said the results "are consistent with a potential disease-modifying effect of solanezumab" and support the use of delayed-start analysis to determine the long-term efficacy and disease-modifying effects of AD treatments. The Alzheimer's Association said the data suggest a benefit from starting solanezumab treatment early in disease progression. ...